BIO Statement on Medicare Part D Changes in Budget Deal
“It is regrettable that such sweeping changes to the successful Medicare Part D program would be considered with so little opportunity for public input or examination of the potential impact on beneficiaries and future biopharmaceutical innovation.
“While we support making out of pocket costs for Part D beneficiaries more affordable, the vast majority of savings from this proposal will accrue to the insurance companies that sponsor Part D plans, rather than patients. America’s biopharmaceutical industry pours far more of its earnings back into R&D than any other sector, approximately 20 percent of all revenue, as companies tirelessly seek to discover new treatments and cures for patients in need. Forcing companies to divert billions of dollars from the research lab to bail out insurance companies will stifle innovation while doing little to save costs for Medicare beneficiaries.
“We stand ready to work with
About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across
Upcoming BIO Events
|
|
||
|
|
||
|
|||
|
|||
View source version on businesswire.com: http://www.businesswire.com/news/home/20180208006508/en/
Web: www.bio.org
Blog: www.biotech-now.org
Twitter: @IAmBiotech
Source:
Seeking Your Say On Life Saving SafeScript Regulations
Private Healthcare Market Sustains Competitiveness by Adoption of Technological Innovations
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News